Presence of CD34(+)CD38(-)CD58(-) leukemia-propagating cells at   diagnosis identifies patients at high risk of relapse with Ph   chromosome-positive ALL after allo-hematopoietic SCT

doi:10.1038/bmt.2014.274

CORC > 北京大学 > 生命科学学院

	Presence of CD34(+)CD38(-)CD58(-) leukemia-propagating cells at diagnosis identifies patients at high risk of relapse with Ph chromosome-positive ALL after allo-hematopoietic SCT
	Kong, Y. ; Xu, L-P ; Liu, Y-R ; Qin, Y-Z ; Sun, Y-Q ; Wang, Y. ; Jiang, H. ; Jiang, Q. ; Chen, H. ; Chang, Y-J ; Huang, X-J
刊名	骨髓移植术
	2015
关键词	ACUTE LYMPHOBLASTIC-LEUKEMIA ACUTE MYELOID-LEUKEMIA MINIMAL RESIDUAL DISEASE MULTICOLOR FLOW-CYTOMETRY POLYMERASE-CHAIN-REACTION TRANSCRIPT LEVELS CANCER PROGRAM IMATINIB TRANSPLANTATION SURVIVAL
DOI	10.1038/bmt.2014.274
英文摘要	Relapse of Ph chromosome-positive ALL (Ph(+)ALL) results from the persistence of leukemia-propagating cells (LPCs). In Ph(+)ALL, a xenograft assay recently determined that LPCs are enriched in the CD34(+)CD38(-)CD58(-) fraction. Therefore, the prognostic significance of LPCs in Ph+ALL subjects after allogeneic hematopoietic SCT (allo-HSCT) was investigated. A total of 80 consecutive adults with Ph+ALL who underwent allo-HSCT were eligible. A multi-parameter flow cytometry analysis examining CD58-FITC/CD10-PE/CD19-APC-Cy7/CD34-PerCP/CD45-Vioblue/CD38-APC on gated leukemia BM blasts was performed at diagnosis. Based on the original blast phenotypes, subjects were stratified into the CD34(+)CD38(-)CD58(-) group (N = 15) and other phenotype group (N = 65). During minimal residual disease monitoring, significantly higher levels of BCR/ABL transcripts were detected in subjects in the CD34(+)CD38(-)CD58(-) group than in other phenotype group, especially at 3 months post HSCT. In addition, CD34(+)CD38(-)CD58(-) LPCs are directly correlated with a higher 3-year cumulative incidence of relapse (CIR) and worse leukemia-free survival (LFS) and OS. Multivariate analyses indicated that presence of CD34(+)CD38(-)CD58(-) LPCs at diagnosis, and BCR-ABL reduction at 3 months post HSCT were independent risk factors for relapse, LFS and OS. Our data suggest that presence of CD34(+)CD38(-)CD58(-) LPCs at diagnosis allows rapid identification of high-risk patients for relapse after allo-HSCT.; Biophysics; Oncology; Hematology; Immunology; Transplantation; SCI(E); PubMed; 0; ARTICLE; huangxiaojun@bjmu.edu.cn; 3; 348-353; 50
语种	英语
内容类型	期刊论文
源URL	[http://ir.pku.edu.cn/handle/20.500.11897/306938]
专题	生命科学学院
推荐引用方式 GB/T 7714	Kong, Y.,Xu, L-P,Liu, Y-R,et al. Presence of CD34(+)CD38(-)CD58(-) leukemia-propagating cells at diagnosis identifies patients at high risk of relapse with Ph chromosome-positive ALL after allo-hematopoietic SCT[J]. 骨髓移植术,2015.
APA	Kong, Y..,Xu, L-P.,Liu, Y-R.,Qin, Y-Z.,Sun, Y-Q.,...&Huang, X-J.(2015).Presence of CD34(+)CD38(-)CD58(-) leukemia-propagating cells at diagnosis identifies patients at high risk of relapse with Ph chromosome-positive ALL after allo-hematopoietic SCT.骨髓移植术.
MLA	Kong, Y.,et al."Presence of CD34(+)CD38(-)CD58(-) leukemia-propagating cells at diagnosis identifies patients at high risk of relapse with Ph chromosome-positive ALL after allo-hematopoietic SCT".骨髓移植术 (2015).